Skip to content

Rheumatoid arthritis — difficult-to-treat and refractory disease

TL;DR — Difficult-to-treat (D2T) RA is not synonymous with cytokine-resistant synovitis. The EULAR definition requires failure of at least two biologic/targeted synthetic DMARDs with different mechanisms after conventional therapy, evidence of active/progressive or symptomatic disease, and management perceived as problematic (Nagy 2021, PMID 33004335). Reported prevalence ranges from about 5.5% to 27.5%, partly because cohorts and definitions differ (Hofman 2025, PMID 39383505). Persistent objective inflammation, structural damage, fibromyalgia/central pain, infection, obesity, mood, adherence, access and misdiagnosis can produce the same high composite score. The first intervention is therefore decomposition: confirm RA, determine whether inflammation is present, and identify modifiable barriers before another mechanism switch (Nagy 2022, PMID 34407926; Buch 2021, PMID 33293696).

EULAR definition

All three domains are required (Nagy 2021, PMID 33004335):

Domain Requirement
Treatment history Failure of ≥2 b/tsDMARDs with different mechanisms after csDMARD treatment unless contraindicated
Disease evidence Active/progressive disease, inability to taper glucocorticoids, rapid radiographic progression, or persistent symptoms reducing quality of life
Problem status Management perceived as problematic by patient and/or rheumatologist

The definition intentionally includes people with low measured inflammatory activity but unacceptable symptoms. It is a serviceable research umbrella, not proof of shared biology.

Inflammatory versus non-inflammatory refractory states

Feature Persistent inflammatory refractory RA Predominantly non-inflammatory refractory state
Swollen joints Present Absent or minimal
CRP/ESR May be raised; can be drug-suppressed Often normal
Ultrasound Doppler Supports active synovitis Quiet or discordant
Radiographic progression May continue Usually reflects prior damage
Pain distribution Joint-centered inflammatory pattern Widespread/neuropathic/mechanical patterns possible
Response to steroids May improve Nonspecific and often transient
Best next step Mechanism reassessment/switch Treat driver; avoid reflex escalation

Buch and colleagues distinguish persistent inflammatory refractory RA from patients whose apparent activity is mainly non-inflammatory (Buch 2021, PMID 33293696). In a 1,591-person treated cohort, ultrasound helped separate inflammatory and non-inflammatory phenotypes within D2T and poly-refractory groups (David 2024, PMID 38059326).

Structured reassessment

Question Checks
Is the diagnosis still RA? Distribution, psoriasis, crystal disease, infection, connective-tissue disease, imaging
Is inflammation active? Swollen joints, CRP/ESR, targeted ultrasound/MRI, radiographic trajectory
Was each drug truly failed? Dose, duration, adherence, combination, intolerance versus inefficacy
Is pharmacokinetics involved? Body size, immunogenicity, route, missed doses
Are symptoms from damage? Osteoarthritis, tendon rupture, deformity, neuropathy
Is pain amplified? Fibromyalgia features, sleep, mood, trauma, deconditioning
Are comorbidities limiting options? Infection, cancer, CV disease, ILD, liver/kidney disease
Are system barriers active? Cost, transport, language, health literacy, fragmented care

Treatment evidence after multiple failures

Randomized trials largely enroll patients after one or more biologic failures, not the full EULAR D2T phenotype. A 2024 network meta-analysis attempted to compare therapies in D2T RA, but indirectness, varied prior mechanisms and short follow-up limit ranking certainty (Su 2024, PMID 39198829).

Upadacitinib improved outcomes versus placebo in SELECT-BEYOND after biologic failure (Genovese 2018, PMID 29908670). Network comparisons find multiple non-TNF biologics and JAK inhibitors effective after TNF failure, without a definitive universal sequence (Sung 2021, PMID 33600008).

Non-pharmacological and service interventions

Driver Intervention domain
Deconditioning Graded strengthening/aerobic exercise
Hand dysfunction Occupational therapy, splints, joint protection
Persistent pain Mechanism-based pain care
Fatigue Sleep, activity, mood and pacing interventions
Adherence barriers Shared decision, simplification, reminders, access support
Smoking/obesity Supported risk-factor care without blame
Work disability Workplace modification and vocational support

An umbrella review found evidence for selected exercise and psychosocial interventions while emphasizing heterogeneity (Rongen-van Santos 2019, PMID 31169776). These are adjuncts, not substitutes for controlling proven synovitis.

Emerging rescue strategies

Six multidrug-resistant patients treated compassionately with low-dose CD19×CD3 blinatumomab had B-cell depletion and rapid clinical improvement, a signal that is mechanistically provocative but far below practice-changing evidence (Bucci 2024, PMID 38671240). CAR-T and deeper immune-reset strategies are entering autoimmune research; infection, cytokine-release, neurotoxicity, cytopenia, cost and durability make controlled trials essential.

Outcomes that matter

Another ACR20 response is insufficient for D2T research. Trials need objective inflammation, pain, fatigue, function, participation, steroid exposure, infection, treatment burden, sustained response and ability to stop ineffective drugs.

Quantified heterogeneity behind the label

Question Evidence Consequence
How common? Twenty-three studies from 13 countries (27,987 patients) produced pooled EULAR-defined D2T prevalence 11.7% (95% CI 9.5–14.3); prevalence was 4.3% after ≥3 advanced-therapy failures and 1.6% after ≥4 (Xie 2026, PMID 41188120). Prevalence depends strongly on the failure threshold; reports must state the definition.
How often persistently inflammatory? Only 47.1% (95% CI 33.3–61.4) of D2T cases had persistent inflammatory refractory disease in the same synthesis (Xie 2026, PMID 41188120). Roughly half require a problem other than automatic mechanism cycling to be addressed.
Can early activity predict it? In 631 incident cases, 35 (5.87%) developed D2T RA; baseline DAS28 was not independently predictive, while disability was (OR 1.89; p=0.01) (Leon 2023, PMID 36889800). High symptom burden may encode damage risk, pain, context, or access as well as inflammation.
How large is assessor discordance? Patient and physician global assessments differed by >20 mm in 61.7% of 467 patients; pain was the dominant correlate (β 0.74, 95% CI 0.62–0.88) (Brites 2021, PMID 34226435). Discordance is a diagnostic signal, not evidence that either perspective is wrong.
What obstructs adherence? D2T patients prioritized adverse events and doubts about effectiveness; patients and clinicians agreed that relationship quality and treatment information facilitate adherence (Roodenrijs 2021, PMID 33560301). Adherence assessment must be collaborative and non-punitive.

The EULAR label is intentionally management-based rather than a claim of drug-resistant synovial biology (Conran 2023, PMID 37776482; de Hair 2018, PMID 29029308). Biopsy-driven studies demonstrate that pathobiology can modify relative response, but reviews still judge routine prediction immature (Lewis 2024, PMID 38008706). The central controversy is whether “refractory” cohorts should be split before trials into inflammatory, structural, nociplastic, adherence/access, and mixed phenotypes; pooling them lowers apparent response and obscures mechanism.

Evidence map

This map adds directly adjacent evidence used to bound interpretation. Inclusion means the record informs this topic or a tightly linked decision; it does not imply that every study supports every conclusion on the page.

Adjacent evidence Relevance to this page
Humby F, et al. R4RA biopsy-driven rituximab versus tocilizumab. Lancet. 2021. (PMID 33485455) Adjacent evidence from biomarkers-and-tissue-precision.md, classification-and-diagnosis.md, clinical-trials-landscape.md, epidemiology-and-burden.md, genetics-environment-and-mucosal-origins.md, overview.md, preclinical-autoimmunity-and-prevention.md, synovial-immunobiology.md
Rivellese F, et al. Synovial biopsy biomarker analysis of R4RA. Nat Med. 2022. (PMID 35589854) Adjacent evidence from biologic-dmards.md, biomarkers-and-tissue-precision.md, clinical-trials-landscape.md, conventional-dmards.md, genetics-environment-and-mucosal-origins.md, jak-inhibitors-and-targeted-therapy.md, preclinical-autoimmunity-and-prevention.md, synovial-immunobiology.md, treat-to-target-and-remission.md
Bhamidipati K, et al. Precision medicine in rheumatoid arthritis. Nat Rev Rheumatol. 2022. (PMID 35248489) Adjacent evidence from biomarkers-and-tissue-precision.md, genetics-environment-and-mucosal-origins.md, preclinical-autoimmunity-and-prevention.md, synovial-immunobiology.md
Atzeni F, et al. Biomarkers in rheumatoid arthritis. Mediators Inflamm. 2017. (PMID 28825772) Adjacent evidence from biomarkers-and-tissue-precision.md, genetics-environment-and-mucosal-origins.md, preclinical-autoimmunity-and-prevention.md, synovial-immunobiology.md
van Heemst J, et al. HLA and rheumatoid arthritis. Ann Med. 2014. (PMID 24813459) Adjacent evidence from biomarkers-and-tissue-precision.md, classification-and-diagnosis.md, genetics-environment-and-mucosal-origins.md, overview.md, preclinical-autoimmunity-and-prevention.md, synovial-immunobiology.md
Perera J, et al. Seropositive and seronegative RA phenotypes, biomarkers and synovium. 2024. (PMID 38727279) Adjacent evidence from biomarkers-and-tissue-precision.md, classification-and-diagnosis.md, genetics-environment-and-mucosal-origins.md, overview.md, preclinical-autoimmunity-and-prevention.md, synovial-immunobiology.md
de Pablo P, et al. Imaging tests predicting RA in unclassified arthritis. RMD Open. 2022. (PMID 34782180) Adjacent evidence from biomarkers-and-tissue-precision.md, classification-and-diagnosis.md, genetics-environment-and-mucosal-origins.md, overview.md, preclinical-autoimmunity-and-prevention.md, synovial-immunobiology.md
Mandl P, et al. Imaging for treat to target in RA. Rheumatology. 2019. (PMID 31518423) Adjacent evidence from biomarkers-and-tissue-precision.md, classification-and-diagnosis.md, conventional-dmards.md, epidemiology-and-burden.md, genetics-environment-and-mucosal-origins.md, overview.md, preclinical-autoimmunity-and-prevention.md, synovial-immunobiology.md, treat-to-target-and-remission.md
He S, et al. Plasma protein biomarkers predating onset and treatment response in RA. 2025. (PMID 40691443) Adjacent evidence from biomarkers-and-tissue-precision.md, genetics-environment-and-mucosal-origins.md, preclinical-autoimmunity-and-prevention.md, synovial-immunobiology.md
Ling SF, et al. Pharmacogenetics of methotrexate response in RA. 2020. (PMID 31849277) Adjacent evidence from biomarkers-and-tissue-precision.md, conventional-dmards.md, genetics-environment-and-mucosal-origins.md, preclinical-autoimmunity-and-prevention.md, synovial-immunobiology.md, treat-to-target-and-remission.md
Caproli A, et al. Calprotectin as a biomarker in RA. 2023. (PMID 37584369) Adjacent evidence from biomarkers-and-tissue-precision.md, genetics-environment-and-mucosal-origins.md, preclinical-autoimmunity-and-prevention.md, synovial-immunobiology.md
Schonfeldova B, et al. Synovial single-cell heterogeneity and zonation. Nat Rev Rheumatol. 2022. (PMID 34559213) Adjacent evidence from biologic-dmards.md, biomarkers-and-tissue-precision.md, genetics-environment-and-mucosal-origins.md, jak-inhibitors-and-targeted-therapy.md, preclinical-autoimmunity-and-prevention.md, synovial-immunobiology.md
van Tuyl LH, et al. Patient-reported outcomes in rheumatoid arthritis. Rheum Dis Clin North Am. 2016. (PMID 27133486) Adjacent evidence from classification-and-diagnosis.md, epidemiology-and-burden.md, overview.md, patient-experience-and-advocacy.md
Michaud K, et al. Systematic literature review of residual symptoms and unmet need in RA. Arthritis Care Res. 2021. (PMID 32619340) Adjacent evidence from conventional-dmards.md, epidemiology-and-burden.md, patient-experience-and-advocacy.md, treat-to-target-and-remission.md
Katz P. Fatigue in rheumatoid arthritis. Curr Rheumatol Rep. 2017. (PMID 28386762) Adjacent evidence from patient-experience-and-advocacy.md
Pope JE. Management of fatigue in rheumatoid arthritis. RMD Open. 2020. (PMID 32385141) Adjacent evidence from epidemiology-and-burden.md, patient-experience-and-advocacy.md
Michaud K, et al. Pain, fatigue and work productivity in RA-BEAM. Rheumatol Ther. 2019;6:409-419. (PMID 31228100) Adjacent evidence from patient-experience-and-advocacy.md
Fraenkel L, et al. 2021 ACR guideline for treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021. (PMID 34101376) Adjacent evidence from biologic-dmards.md, classification-and-diagnosis.md, conventional-dmards.md, epidemiology-and-burden.md, guidelines.md, jak-inhibitors-and-targeted-therapy.md, overview.md, patient-experience-and-advocacy.md, treat-to-target-and-remission.md
Grigor C, et al. TICORA tight-control trial. Lancet. 2004. (PMID 15262104) Adjacent evidence from classification-and-diagnosis.md, clinical-trials-landscape.md, conventional-dmards.md, epidemiology-and-burden.md, genetics-environment-and-mucosal-origins.md, overview.md, preclinical-autoimmunity-and-prevention.md, treat-to-target-and-remission.md
Korpela M, et al. FIN-RACo five-year outcomes. Arthritis Rheum. 2004. (PMID 15248204) Adjacent evidence from classification-and-diagnosis.md, clinical-trials-landscape.md, conventional-dmards.md, epidemiology-and-burden.md, genetics-environment-and-mucosal-origins.md, overview.md, preclinical-autoimmunity-and-prevention.md, treat-to-target-and-remission.md
Evidence-map records are listed in full below and were live-retrieved from PubMed in this build session.

Open questions

  • What proportion of D2T RA has tissue-confirmed persistent inflammation versus non-inflammatory symptom amplification? (David 2024, PMID 38059326)
  • Should D2T trials stratify by synovial pathotype before randomization?
  • What is the best sequence after two mechanistically distinct failures? (Su 2024, PMID 39198829)
  • Can adherence/access interventions prevent entry into the D2T state?
  • Are immune-reset approaches durable enough to justify their acute risk? (Bucci 2024, PMID 38671240)

References

  1. Nagy G, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021;80:31-35. PMID 33004335
  2. Hofman ZLM, et al. Difficult-to-treat rheumatoid arthritis: what have we learned and what do we still need to learn?. Rheumatology (Oxford). 2025;64:65-73. PMID 39383505
  3. Nagy G, et al. EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2022;81:20-33. PMID 34407926
  4. Buch MH, et al. Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis. Nat Rev Rheumatol. 2021;17:17-33. PMID 33293696
  5. David P, et al. Poly-Refractory Rheumatoid Arthritis: An Uncommon Subset of Difficult to Treat Disease With Distinct Inflammatory and Noninflammatory Phenotypes. Arthritis Rheumatol. 2024;76:510-521. PMID 38059326
  6. Su QY, et al. Efficacy and safety of current therapies for difficult-to-treat rheumatoid arthritis: a systematic review and network meta-analysis. J Transl Med. 2024;22:795. PMID 39198829
  7. Genovese MC, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018;391:2513-2524. PMID 29908670
  8. Sung YK, et al. Comparative effectiveness and safety of non-tumour necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumour necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials. J Clin Pharm Ther. 2021;46:984-992. PMID 33600008
  9. Santos EJF, et al. Effectiveness of non-pharmacological and non-surgical interventions for rheumatoid arthritis: an umbrella review. JBI Database System Rev Implement Rep. 2019;17:1494-1531. PMID 31169776
  10. Bucci L, et al. Bispecific T cell engager therapy for refractory rheumatoid arthritis. Nat Med. 2024;30:1593-1601. PMID 38671240
  11. Xie W, et al. Difficult-to-treat rheumatoid arthritis: systematic review and meta-analysis on global prevalence. Ann Rheum Dis. 2026;85:417-424. PMID 41188120
  12. Leon L, et al. Difficult-to-treat rheumatoid arthritis (D2T RA): clinical issues at early stages of disease. RMD Open. 2023;9:e002842. PMID 36889800
  13. Brites L, et al. Patient-Physician discordance in assessment of disease activity in Rheumatoid Arthritis patients. Acta Reumatol Port. 2021;46:103-109. PMID 34226435
  14. Roodenrijs NMT, et al. Non-adherence in difficult-to-treat rheumatoid arthritis from the perspectives of patients and rheumatologists: a concept mapping study. Rheumatology (Oxford). 2021;60:5105-5116. PMID 33560301
  15. Conran C, et al. A Review of Difficult-to-Treat Rheumatoid Arthritis: Definition, Clinical Presentation, and Management. Curr Rheumatol Rep. 2023;25:285-294. PMID 37776482
  16. de Hair MJH, et al. Difficult-to-treat rheumatoid arthritis: an area of unmet clinical need. Rheumatology (Oxford). 2018;57:1135-1144. PMID 29029308
  17. Lewis MJ, et al. Predicting best treatment in rheumatoid arthritis. Semin Arthritis Rheum. 2024;64S:152329. PMID 38008706
  18. Humby F, et al. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet. 2021;397:305-317. PMID 33485455
  19. Rivellese F, et al. Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. Nat Med. 2022;28:1256-1268. PMID 35589854
  20. Bhamidipati K, et al. Precision medicine in rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2022;36:101742. PMID 35248489
  21. Atzeni F, et al. Biomarkers in Rheumatoid Arthritis. Isr Med Assoc J. 2017;19:512-516. PMID 28825772
  22. van Heemst J, et al. HLA and rheumatoid arthritis: how do they connect?. Ann Med. 2014;46:304-10. PMID 24813459
  23. Perera J, et al. Clinical Phenotypes, Serological Biomarkers, and Synovial Features Defining Seropositive and Seronegative Rheumatoid Arthritis: A Literature Review. Cells. 2024;13:743. PMID 38727279
  24. de Pablo P, et al. Systematic review of imaging tests to predict the development of rheumatoid arthritis in people with unclassified arthritis. Semin Arthritis Rheum. 2022;52:151919. PMID 34782180
  25. Mandl P, et al. The role of ultrasound and magnetic resonance imaging for treat to target in rheumatoid arthritis and psoriatic arthritis. Rheumatology (Oxford). 2019;58:2091-2098. PMID 31518423
  26. He S, et al. A longitudinal cohort study uncovers plasma protein biomarkers predating clinical onset and treatment response of rheumatoid arthritis. Nat Commun. 2025;16:6692. PMID 40691443
  27. Ling SF, et al. Pharmacogenetics of methotrexate response in rheumatoid arthritis: an update. Pharmacogenomics. 2020;21:3-6. PMID 31849277
  28. Caproli A, et al. Calprotectin as a biomarker in rheumatoid arthritis: the potential predictive value of response to treatment. Bioanalysis. 2023;15:1111-1113. PMID 37584369
  29. Schonfeldova B, et al. Synovial single-cell heterogeneity, zonation and interactions: a patchwork of effectors in arthritis. Rheumatology (Oxford). 2022;61:913-925. PMID 34559213
  30. van Tuyl LH, et al. Patient-Reported Outcomes in Rheumatoid Arthritis. Rheum Dis Clin North Am. 2016;42:219-37. PMID 27133486
  31. Michaud K, et al. Systematic Literature Review of Residual Symptoms and an Unmet Need in Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021;73:1606-1616. PMID 32619340
  32. Katz P, et al. Fatigue in Rheumatoid Arthritis. Curr Rheumatol Rep. 2017;19:25. PMID 28386762
  33. Pope JE, et al. Management of Fatigue in Rheumatoid Arthritis. RMD Open. 2020;6:e001084. PMID 32385141
  34. Michaud K, et al. Relative Impact of Pain and Fatigue on Work Productivity in Patients with Rheumatoid Arthritis from the RA-BEAM Baricitinib Trial. Rheumatol Ther. 2019;6:409-419. PMID 31228100
  35. Fraenkel L, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2021;73:1108-1123. PMID 34101376
  36. Grigor C, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364:263-9. PMID 15262104
  37. Korpela M, et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum. 2004;50:2072-81. PMID 15248204